Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

113 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Thomaidis T, Maderer A, Al-Batran SE, Kany J, Pauligk C, Steinmetz K, Schad A, Hofheinz R, Schmalenberg H, Homann N, Galle PR, Moehler M. Thomaidis T, et al. Among authors: schad a. BMC Cancer. 2014 Jul 1;14:476. doi: 10.1186/1471-2407-14-476. BMC Cancer. 2014. PMID: 24981311 Free PMC article. Clinical Trial.
Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program.
Moehler M, Maderer A, Ehrlich A, Foerster F, Schad A, Nickolay T, Ruckes C, Weinmann A, Sivanathan V, Marquardt JU, Galle PR, Woerns M, Thomaidis T. Moehler M, et al. Among authors: schad a. BMC Cancer. 2019 Jan 11;19(1):55. doi: 10.1186/s12885-018-5223-7. BMC Cancer. 2019. PMID: 30634942 Free PMC article. Clinical Trial.
Lapatinib with ECF/X in the first-line treatment of metastatic gastric cancer according to HER2neu and EGFR status: a randomized placebo-controlled phase II study (EORTC 40071).
Moehler M, Schad A, Maderer A, Atasoy A, Mauer ME, Caballero C, Thomaidis T, John JMM, Lang I, Van Cutsem E, Freire J, Lutz MP, Roth A; EORTC Gastrointestinal Tract Cancer Group. Moehler M, et al. Among authors: schad a. Cancer Chemother Pharmacol. 2018 Oct;82(4):733-739. doi: 10.1007/s00280-018-3667-8. Epub 2018 Aug 13. Cancer Chemother Pharmacol. 2018. PMID: 30105460 Clinical Trial.
Protective effects of ischemic preconditioning and application of lipoic acid prior to 90 min of hepatic ischemia in a rat model.
Duenschede F, Erbes K, Riegler N, Ewald P, Kircher A, Westermann S, Schad A, Miesmer I, Albrecht-Schöck S, Gockel I, Kiemer AK, Junginger T. Duenschede F, et al. Among authors: schad a. World J Gastroenterol. 2007 Jul 21;13(27):3692-8. doi: 10.3748/wjg.v13.i27.3692. World J Gastroenterol. 2007. PMID: 17659728 Free PMC article.
Acute organ failure following the loss of anti-apoptotic cellular FLICE-inhibitory protein involves activation of innate immune receptors.
Gehrke N, Garcia-Bardon D, Mann A, Schad A, Alt Y, Wörns MA, Sprinzl MF, Zimmermann T, Menke J, Engstler AJ, Bergheim I, He YW, Galle PR, Schuchmann M, Schattenberg JM. Gehrke N, et al. Among authors: schad a. Cell Death Differ. 2015 May;22(5):826-37. doi: 10.1038/cdd.2014.178. Epub 2014 Oct 24. Cell Death Differ. 2015. PMID: 25342470 Free PMC article.
Proteins of the VEGFR and EGFR pathway as predictive markers for adjuvant treatment in patients with stage II/III colorectal cancer: results of the FOGT-4 trial.
Thomaidis T, Maderer A, Formentini A, Bauer S, Trautmann M, Schwarz M, Neumann W, Kittner JM, Schad A, Link KH, Rey JW, Weinmann A, Hoffman A, Galle PR, Kornmann M, Moehler M. Thomaidis T, et al. Among authors: schad a. J Exp Clin Cancer Res. 2014 Oct 2;33(1):83. doi: 10.1186/s13046-014-0083-8. J Exp Clin Cancer Res. 2014. PMID: 25272957 Free PMC article.
113 results